The clinical potential of Deprenyl in neurologic and psychiatric disorders

  • W. Kuhn
  • Th. Müller
Conference paper
Part of the Journal of Neural Transmission book series (NEURAL SUPPL, volume 48)


This article reviews the results of clinical studies with Deprenyl in various neurologic and psychiatric disorders except Parkinson’s disease. Promising results could be observed both in narcolepsy in a dose of at least 20 mg/day in three different trials and in one study of Tourette’s syndrome including attention hyperactivity disorders using an average dosis of 8.1 mg/ day. Controversial results were reported for Alzheimer’s disease. On the one hand significant improvement of cognitive functions was found by various authors. On the other hand in a more recent study no effect on the progression of the disease could be observed. For depression a higher dosage of deprenyl between 30 to 60 mg/day appears to be necessary for effective treatment. No positive results were found in amyotrophic lateral sclerosis and in tardive dyskinesias.


Amyotrophic Lateral Sclerosis Negative Symptom Progressive Supranuclear Palsy Tardive Dyskinesia Progressive Supranuclear Palsy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Agid Y, Javoy-Agid F, Ruberg M, et al (1986) Progressive supranuclear palsy: anatomoclinical and biochemical considerations. Adv Neurol 45: 191–206Google Scholar
  2. Agnoli A, Martucci N, Fabbrini G, et al (1990) Monoamine oxidase and dementia: treatment with an inhibitor of MAO-B activity. Dementia 1: 109–114Google Scholar
  3. Baldessarini RJ (1979) Neurological toxicology of antipyschotic drugs. McLean Hosp J 4:2–19Google Scholar
  4. Bamford CR, Montgomery EB Jr, Munoz JE, et al (1993) Postpolio syndrome-response to deprenyl (selegiline). Int J Neurosci 71(1–4): 183–188PubMedCrossRefGoogle Scholar
  5. Bucci L (1987) The negative symptoms of schizophrenia and the monoamine oxidase inhibitors. Psychopharmacology 91: 104–108PubMedCrossRefGoogle Scholar
  6. Burke WJ, Roccaforte WH, Wengel SP, et al (1993) L-Deprenyl in the treatment of mild dementia of the Alzheimer type: results of a IS-month trial. J Am Geriatr Soc 41(11): 1219–225PubMedGoogle Scholar
  7. Campi N, Todeschini GP, Scarzella L (1990) Selegiline versus L-acetylcarnitine in the treatment of Alzheimer type dementia. Clin Ther 12: 306–314PubMedGoogle Scholar
  8. Chouinard G, Jones BD, Annable L (1980) L-dopa in neuroleptic induced extrapyramidal symptoms. 35th Annual Convention of Society of Biological Psychiatry of USA, BostonGoogle Scholar
  9. Cohen G, Spina MB (1989) Deprenyl suppresses the oxidant stress associated with increased dopamine turn-over. Ann Neurol 26: 689–690PubMedCrossRefGoogle Scholar
  10. Crow TJ (1980) Molecular pathology of schizophrenia: more than one disease process? Br Med J 280: 66–68PubMedCrossRefGoogle Scholar
  11. Gewirtz GR, Sharif Z, Cadet JL, Sarti P, Gorman JM (1993) Selegiline for neuroleptic-induced Parkinsonism. Pharmacopsychiat 26: 128–129CrossRefGoogle Scholar
  12. Goff DC, Renshaw PF, Sarid-Segal O, et al (1993) A placebo-controlled trial of selegiline (L-deprenyl) in the treatment of tardive dyskinesia. Biol Psychiatry 33: 700–706PubMedCrossRefGoogle Scholar
  13. Heinonen EH, Lammintausta R (1991) A review of the pharmacology of selegiline. Acta Neurol Scand 136 [Suppl]: 44–59CrossRefGoogle Scholar
  14. Hublin C, Partinen M, Heinonen EH, Punkka P, Salmi T (1994) Selegiline in the treatment of narcolepsy. Neurology 44: 2095–2101PubMedGoogle Scholar
  15. Jankovic J (1992) Diagnosis and classification of tics and Tourette Syndrome. Adv Neurol 58: 7–14PubMedGoogle Scholar
  16. Jankovic J (1993) Deprenyl in attention deficit associated with Tourette’s syndrome. Arch Neurol 50:286–288PubMedCrossRefGoogle Scholar
  17. Jossan SS, Ekblom J, Gudjonsson O, Hagbarth KE (1994) Double blind cross over trial with deprenyl in amyotrophic lateral sclerosis. J Neural Transm [Suppl] 41: 237–241Google Scholar
  18. Knoll J (1989) The pharmacology of selegiline ((−)deprenyl). New aspects. Acta Neurol Scand 126 [Suppl]: 83–91CrossRefGoogle Scholar
  19. Knoll J, Magyar K (1972) Some puzzling pharmacological effects of monoamine oxidase inhibitors. In: Costa E, Sandler M (eds) Monoamine oxidase — new vistas. Raven Press, New York, pp 393–408Google Scholar
  20. Kuritzky A, Zoldan Y, Melamed E (1992) Selegiline, a MAO-B inhibitor, is not effective in the prophylaxis of migraine without aura — an open study. Headache 32(8): 416PubMedCrossRefGoogle Scholar
  21. Lavie P, Wajsbort J, Youdim MBH (1980) Deprenyl does not cause insomnia in parkinsonian patients. Commun Psychopharmacol 4: 303–307PubMedGoogle Scholar
  22. Lohr JB (1991) Oxygen radicals and neuropsychiatric illness. Arch Gen Pschiatry 48: 1097–1106CrossRefGoogle Scholar
  23. Mangoni A, Grassi MP, Frattola L, Piolti R, Bassi S, Motta A, Marcone A, Smirne S (1991) Effects of a MAO-B inhibitor in the treatment of Alzheimer’s disease. Eur Neurol 31: 100–107PubMedCrossRefGoogle Scholar
  24. Mann J, Gershon S (1980) L-Deprenyl, a selective monoamine oxidase type-B inhibitor in endogenous depression. Life Sci 26: 877–882PubMedCrossRefGoogle Scholar
  25. Mann JJ, Frances A, Kaplan RD, et al (1982) The relative efficacy of 1-Deprenyl, a selective monoamine oxidase type B inhibitor, in endogenous and nonendogenous depression. J Clin Psychopharmacol 2(sn1): 54–57PubMedCrossRefGoogle Scholar
  26. Mann JJ, Aarons SF, Wilner PJ, Keilp JG, Sweeney JA, Pearlstein T, Frances AJ, Kocsis JH, Brown RP (1989) A controlled study of the antidepressant efficacy and side effects of (−)-deprenyl: a selective monoamine oxidase inhibitor. Arch Gen Psychiatry 46: 45–50PubMedCrossRefGoogle Scholar
  27. Mayer G, Ewert Meier K, Klinik Hephata (1995) Selegiline Hydrochloride treatment in narcolepsy. A double-blind, placebo-controlled study. Clin Neuropharmacol 18/4: 306–319PubMedCrossRefGoogle Scholar
  28. Mazzini L, Testa D, Balzarini C, Mora G (1994) An open-randomized clinical trial of selegiline in amyotrophic lateral sclerosis. J Neurol 241: 223–227PubMedCrossRefGoogle Scholar
  29. Meltzer HY, Sommers AA, Luchins DJ (1986) The effect of neuroleptics and other psychotropic drugs on negative symptoms in schizphrenia. J Clin Psychopharmacol 6: 329–338PubMedCrossRefGoogle Scholar
  30. Mendis N, Pare CMB, Sandler M, et al (1981) Deprenyl in the treatment of depression. In: Youdim MBH, Paykel ES (eds) Monoamine oxidase inhibitors: the state of the art. John Wiley and Sons, Chichester, pp 171–176Google Scholar
  31. Mendlewicz J, Youdim MBH (1983) L-Deprenyl, a selective monoamine oxidase type B inhibitor, and the treatment of depression: a double blind evaluation. Br J Psychiatry 142: 508–511PubMedCrossRefGoogle Scholar
  32. Mitchell JD, Houghton E, Kilshow J, et al (1993) Free radicals, sporadic motor neurone disease and selegiline. Symposium on Neuroprotection and clinical trials in MND/ ALS, Paris (Abstract)Google Scholar
  33. Monteverde A, Gnemmi P, Rossi F, Monteverde A (1990) Selegiline in the treatment of mild to moderate Alzheimer type dementia. Clin Ther 12: 315–322PubMedGoogle Scholar
  34. Nakamura S, Kawamata T, Akiguchi I, Kameyama M, Nakamura N, Kimura H (1990) Expression of monoamine oxidase B activity in astrocytes of senile plaques. Acta Neuropathol 80: 419–425PubMedCrossRefGoogle Scholar
  35. Nieforth KA, Golbe LI (1993) Retrospective study of drug response in 87 patients with progressive supranuclear palsy. Clin Neuropharmacol 16/4: 338–346PubMedCrossRefGoogle Scholar
  36. Oreland L, Gottfries CG (1986) Brain and brain monoamine oxidase in aging and in dementia of Alzheimer’s type. Prog Neuropsychopharmacol Biol Psychiatry 10: 533–540PubMedCrossRefGoogle Scholar
  37. Perenyi A, Bagdy G, Arato M (1983) An early phase II trial with l-deprenyl for the treatment of neuroleptic-induced Parkinsonism. Pharmacopsychiat 16: 143–146CrossRefGoogle Scholar
  38. Perenyi A, Goswami U, Frecska E, Arata M, Bela A (1992) L-Deprenyl in treating negative symptoms of schizophrenia. Psychiatry Res 42: 189–191PubMedCrossRefGoogle Scholar
  39. Piccinin GL, Finali G, Piccarilli M (1990) Neuropsychological effects of L-deprenyl in Alzheimer’s dementia. Clin Neuropharmacol 13: 147–163PubMedCrossRefGoogle Scholar
  40. Quitkin FM, Liebowitz MR, Stewart JW, McGrath PJ, Harrison W, Rabkin JG, Markowitz J, Davies SO (1984) L-Deprenyl in a typical depressives. Arch Gen Psychiatry 41: 777–781PubMedCrossRefGoogle Scholar
  41. Quitkin FM, Liebowitz MR, Stewart JW, et al (1985) Deprenyl in atypical depressives. I. Clinical efficacy. Proceedings of the International Symposium in Deprenyl. Chinoin, Budapest, pp 115–119Google Scholar
  42. Roselar SE, Langdon N, Lock CB, Jenner P, Parkes JD (1987) Selegiline in narcolepsy. Sleep 10(5): 491–495Google Scholar
  43. Schachter M, Price PA, Parkes JD (1979) Deprenyl in narcolepsy. Lancet i: 831–832Google Scholar
  44. Schneider LS, Olin JT, Pawluczyk S (1993) A double-blind crossover pilot study of l-deprenyl (selegiline) combined with cholinesterase inhibitor in Alzheimer’s disease. Am J Psychiatry 150: 321–323PubMedGoogle Scholar
  45. Sunderland T, Cohen R, Molchan S, et al (1994) High dose selegiline in treatmentresistant older depressive patients. Arch Gen Psychiatry 51: 607–615PubMedCrossRefGoogle Scholar
  46. Tariot PN, Cohen R, Sunderland T, et al (1987a) L-Deprenyl in Alzheimer’s disease. Arch Gen Psychiatry 44: 427–433PubMedCrossRefGoogle Scholar
  47. Tariot PN, Sunderland T, Weingartner H, et al (1987b) Cognitive effects of L-deprenyl in Alzheimer’s disease. Psychopharmcology 91: 489–495CrossRefGoogle Scholar
  48. Tatton WG (1993) Selegiline can mediate neuronal rescue rather than neuronal protection. Mov Disord 8: 520–530CrossRefGoogle Scholar
  49. Thornton C, Dore CJ, Elsworth JD, Herbert M, Stern GM (1980) The effect of Deprenyl, a selective monoamine oxidase B inhibitor, on sleep and mood in man. Psychopharmcol 70: 163–166CrossRefGoogle Scholar
  50. Tringer L, Haits G, Varga E (1971) The effect of L-E-280 (L-phenylisopropyl-methyl-propinylamine) in depression. Soc Pharmacol Hungarica, Budapest, pp 111–113Google Scholar
  51. Varga E, Tringer L (1967) Clinical trial of a new type of promptly acting psychoenergetic agent (Phenyl-isopropyl-methyl propinyl-HCL, E 250). Acta Med Acad Sci Hung 23: 289–295PubMedGoogle Scholar

Copyright information

© Springer-Verlag/Wien 1996

Authors and Affiliations

  • W. Kuhn
    • 1
  • Th. Müller
    • 1
  1. 1.Department of NeurologySt. Josef-HospitalBochumGermany

Personalised recommendations